Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial
The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Background: Depression is a well-known complication of breast cancer, which is known to adversely affect quality of life, prognosis, and survival in breast cancer patients. Celecoxib, a nonsteroidal anti-inflammatory drug, which acts via the selective inhibition of cyclo-oxygenase (COX)-2, has been shown to have antidepressive effects. Objectives: Here, we aimed to compare the efficacy and safety of celecoxib, a selective inhibitor of COX-2, with diclofenac, a nonselective inhibitor of both COX-1 and COX-2 in reducing depressive symptoms and pain in breast cancer patients. Methods: A total of 52 outpatients with breast cancer with mild to moderate depression, who suffered from pain and needed analgesics, participated in the trial and underwent 6 weeks of treatment with either celecoxib (200 mg twice daily) or diclofenac (50 mg twice daily). Participants were investigated using the Hamilton Depression Rating Scale (HDRS). The primary outcome measure was to compare the antidepressant effects of celecoxib and diclofenac. Results: Repeated-measures analysis demonstrated significant effect for Time × Treatment interaction on the HDRS scores: F(1.76, 87.85) = 9.66; P < 0.001. By study conclusion, greater improvement was observed in the HDRS score of the celecoxib group compared with the diclofenac group ( P = 0.002). No one experienced remission (HDRS ≤ 7) in either group. Frequencies of adverse events were not significantly different between groups. Conclusion: Celecoxib seems to possess superior antidepressive effects compared with diclofenac in breast cancer patients with mild to moderate depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two RCTs, not included in the Cochrane review, investigated the effect of celecoxib, a nonsteroidal antiinflammatory drug that acts via the selective inhibition of cyclooxygenase (COX)-2, on depression at 4 and 6 weeks in patients with cancer.66,86”
From Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023) · cites this paper as [86]
In the citing paper
“However, both trials were small, with 52 and 40 participants, respectively, and included samples in which a COX-2 inhibitor might have also contributed to improved physical symptoms.”
From Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023) · cites this paper as [86]
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Prevalence of depression in patients with cancer
Massie, M. J. (2004) · Journal of the National Cancer Institute Monographs · doi:10.1093/jncimonographs/lgh014 · Cited by 1,408
Celecoxib for the Prevention of Colorectal Adenomatous Polyps
Arber, N., Eagle, C. J., Spicak, J., Rácz, I., Dite, P., Hajer, J., Zavoral, M., Lechuga, M. J., Gerletti, P., Tang, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061652 · Cited by 975
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397
Self-citationAbbasi, S.-H., Hosseini, F., Modabbernia, A., Ashrafi, M., & Akhondzadeh, S. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.03.033 · Cited by 339
Self-citationAKHONDZADEH, S., TABATABAEE, M., AMINI, H., AHMADIABHARI, S., ABBASI, S., & BEHNAM, B. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.11.016 · Cited by 289
Self-citationCella, D., & Fallowfield, L. J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9548-1 · Cited by 286 · cited 1×
“These drugs are used as first-line analgesics in cancer patients with bone metastasis, and they are also administrated routinely for pain relief in breast cancer patients with arthralgia resulting from the use of aromatase inhibitors.(8,9) 592215 AOPXXX10.”
Background
Research works printed but not linked: 5
- Lueboonthavatchai P, 2007, J Med Assoc Thai, 90, 2164
- Kalalinia F, 2014, Iran J Pharm Res, 13, 1393
- Kargar M, 2014, Swiss Med Wkly, 144, w13880
- 10.1177/014107680609900315 · doi:10.1177/014107680609900315 · Paper page
- De Vecchis R, 2014, Minerva Cardioangiol, 62, 437
Cited by
Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update
Andersen, B. L., Lacchetti, C., Ashing, K., Berek, J. S., Berman, B. S., Bolte, S., Dizon, D. S., Given, B., Nekhlyudov, L., Pirl, W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00293 · Cited by 318
Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152
Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
Husain, M. I., Strawbridge, R., Stokes, P. R., & Young, A. H. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725711 · Cited by 139
Neuroimmunology of Behavioral Comorbidities Associated With Cancer and Cancer Treatments
Santos, J. C., & Pyter, L. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01195 · Cited by 121
Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults
Derry, S., Wiffen, P. J., Moore, A., McNicol, E. D., Bell, R. F., Carr, D. B., McIntyre, M., & Wee, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012638.pub2 · Cited by 150
Metadata
- Authors
- Mohammadinejad, P., Arya, P., Esfandbod, M., Kaviani, A., Najafi, M., Kashani, L., Zeinoddini, A., Emami, S. A., & Akhondzadeh, S.
- Affiliations
- Tehran University of Medical Sciences (IR)
- Corresponding author
- Akhondzadeh, Shahin
- ORCID
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2015-07-02
- Volume
- 49
- Issue
- 9
- Pages
- 953-961
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2220990132
- Cited by
- 39
- References
- 47
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 6 · 2022: 6 · 2021: 1 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 7 · 2016: 3 · 2015: 1
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tehran University of Medical Sciences and Health Services
- Topics
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- celecoxib, diclofenac, breast cancer, depression, antidepressant effects, COX-2 inhibition, cyclooxygenase inhibitors, cancer pain, analgesia, Hamilton Depression Rating Scale, adverse events
- MeSH terms
- Celecoxib, Analgesics, Antidepressive Agents, Breast Neoplasms, Depression, Diclofenac, Double-Blind Method, Female, Humans, Middle Aged, Quality of Life, Cyclooxygenase Inhibitors, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial. https://app.cochat.ai/papers/10.1177/1060028015592215
- The paper
- Mohammadinejad, P., Arya, P., Esfandbod, M., Kaviani, A., Najafi, M., Kashani, L., Zeinoddini, A., Emami, S. A., & Akhondzadeh, S. (2015). Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028015592215
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.